Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A

Around one third of boys with severe hemophilia A develop inhibitors (neutralizing antibodies) against their therapeutic factor VIII product. This adverse effect may result in more life-threatening bleeding, disability, impaired quality of life, and costly care. We compared the incidence of inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Calvez, Thierry, Chambost, Hervé, d’Oiron, Roseline, Dalibard, Vincent, Demiguel, Virginie, Doncarli, Alexandra, Gruel, Yves, Huguenin, Yoann, Lutz, Patrice, Rothschild, Chantal, Vinciguerra, Christine, Goudemand, Jenny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777205/
https://www.ncbi.nlm.nih.gov/pubmed/29025913
http://dx.doi.org/10.3324/haematol.2017.174706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777205/
https://www.ncbi.nlm.nih.gov/pubmed/29025913
http://dx.doi.org/10.3324/haematol.2017.174706

Ejemplares similares